Data Year:

For its 2025 fiscal year, IDEXX LABORATORIES INC /DE, listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Brian P. McKeon
Former Executive Vice President, Chief Financial Officer and Treasurer
Total Compensation $351,680 View details Pay Rank By Title In Biotechnology industry #562 View more
Michael J. Lane
Executive Vice President and General Manager, CAG Diagnostics Business Unit
Total Compensation $4,019,416 View details Pay Rank By Title In Biotechnology industry #58 View more
Jonathan J. Mazelsky
President and Chief Executive Officer
Total Compensation $14,580,122 View details Pay Rank By Title In Biotechnology industry #61 View more
Tina Hunt PhD
Executive Vice President, Global Strategy and Commercial
Total Compensation $3,945,293 View details Pay Rank By Title In Biotechnology industry #63 View more
Martin Smith PhD
Executive Vice President and Chief Technology Officer, R&D, Global Operations, Information Technology and Information Security
Total Compensation $3,944,534 View details Pay Rank By Title In Biotechnology industry #64 View more
Andrew Emerson
Executive Vice President and Chief Financial Officer
Total Compensation $3,033,071 View details Pay Rank By Title In Biotechnology industry #151 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at IDEXX LABORATORIES INC /DE as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. IDEXX LABORATORIES INC /DE income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. IDEXX LABORATORIES INC /DE annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Brian P. McKeon
Former Executive Vice President, Chief Financial Officer and Treasurer
Total Cash $293,404 Equity $0 Other $58,276 $351,680
Michael J. Lane
Executive Vice President and General Manager, CAG Diagnostics Business Unit
Total Cash $1,221,324 Equity $2,699,804 Other $98,288 $4,019,416
Jonathan J. Mazelsky
President and Chief Executive Officer
Total Cash $3,743,000 Equity $10,799,882 Other $37,240 $14,580,122
Tina Hunt PhD
Executive Vice President, Global Strategy and Commercial
Total Cash $1,221,324 Equity $2,699,804 Other $24,165 $3,945,293
Martin Smith PhD
Executive Vice President and Chief Technology Officer, R&D, Global Operations, Information Technology and Information Security
Total Cash $1,221,324 Equity $2,699,804 Other $23,406 $3,944,534
Andrew Emerson
Executive Vice President and Chief Financial Officer
Total Cash $1,108,646 Equity $1,899,805 Other $24,620 $3,033,071
For its 2025 fiscal year, IDEXX LABORATORIES INC /DE, listed the following CEO pay ratio data on its annual proxy statement to the SEC.
CEO Name CEO Pay Median Employee Pay CEO Pay Ratio
Jonathan J. Mazelsky CEO Pay $14,580,122 Median Employee Pay $66,956 CEO Pay Ratio 218:1
For its 2025 fiscal year, IDEXX LABORATORIES INC /DE, listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Asha S. Collins, PhD Total Cash $22,500
Bruce L. Claflin Total Cash $347,469
Daniel M. Junius Total Cash $369,969
Irene Chang Britt Total Cash $372,469
Joseph L. (Jay) Hooley Total Cash $251,105
Karen Peacock Total Cash $168,083
Lawrence D. Kingsley Total Cash $499,842
M. Anne Szostak Total Cash $372,469
Sam Samad Total Cash $347,469
Sophie V. Vandebroek, PhD Total Cash $339,969
Stuart M. Essig, PhD Total Cash $354,969
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.